ondansetron has been researched along with Obesity in 4 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present work was to investigate the role of ondansetron on the high fat diet (HFD) induced obese mice for behavioral and biochemical alterations using chronic unpredictable mild stress (CUMS) model of depression." | 7.80 | Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests. ( Gupta, D; Kurhe, Y; Radhakrishnan, M, 2014) |
| "In obese patients, the incidence of postoperative nausea and vomiting (PONV) following sleeve gastrectomy under titration of total intravenous anaesthesia (TIVA) and the relevance of risk factors to indicate prophylaxis is unknown." | 6.82 | Impact of a prophylactic combination of dexamethasone-ondansetron on postoperative nausea and vomiting in obese adult patients undergoing laparoscopic sleeve gastrectomy during closed-loop propofol-remifentanil anaesthesia: A randomised double-blind place ( Bataille, A; Charmeau, A; Chazot, T; Diemunsch, P; Fischler, M; Le Guen, M; Léger, P; Lemedioni, P; Letourneulx, JF; Liu, N, 2016) |
| "Because practitioners have taken widely differing approaches to the selection and dosing of agents in this class, this retrospective study assessed the relative efficacy of i." | 5.31 | Efficacy of single-dose intravenous dolasetron versus ondansetron in the prevention of postoperative nausea and vomiting. ( Walker, JB, 2001) |
| "The aim of the present work was to investigate the role of ondansetron on the high fat diet (HFD) induced obese mice for behavioral and biochemical alterations using chronic unpredictable mild stress (CUMS) model of depression." | 3.80 | Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests. ( Gupta, D; Kurhe, Y; Radhakrishnan, M, 2014) |
| "In obese patients, the incidence of postoperative nausea and vomiting (PONV) following sleeve gastrectomy under titration of total intravenous anaesthesia (TIVA) and the relevance of risk factors to indicate prophylaxis is unknown." | 2.82 | Impact of a prophylactic combination of dexamethasone-ondansetron on postoperative nausea and vomiting in obese adult patients undergoing laparoscopic sleeve gastrectomy during closed-loop propofol-remifentanil anaesthesia: A randomised double-blind place ( Bataille, A; Charmeau, A; Chazot, T; Diemunsch, P; Fischler, M; Le Guen, M; Léger, P; Lemedioni, P; Letourneulx, JF; Liu, N, 2016) |
| "Because practitioners have taken widely differing approaches to the selection and dosing of agents in this class, this retrospective study assessed the relative efficacy of i." | 1.31 | Efficacy of single-dose intravenous dolasetron versus ondansetron in the prevention of postoperative nausea and vomiting. ( Walker, JB, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kurhe, Y | 2 |
| Radhakrishnan, M | 1 |
| Gupta, D | 1 |
| Mahesh, R | 1 |
| Bataille, A | 1 |
| Letourneulx, JF | 1 |
| Charmeau, A | 1 |
| Lemedioni, P | 1 |
| Léger, P | 1 |
| Chazot, T | 1 |
| Le Guen, M | 1 |
| Diemunsch, P | 1 |
| Fischler, M | 1 |
| Liu, N | 1 |
| Walker, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Should we Associate Dexamethasone and Ondansetron to Closed-loop Anesthesia to Reduce the Incidence of Postoperative Nausea and Vomiting After Bariatric Surgery?[NCT01876290] | Phase 4 | 122 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ondansetron and Obesity
| Article | Year |
|---|---|
Impact of a prophylactic combination of dexamethasone-ondansetron on postoperative nausea and vomiting in obese adult patients undergoing laparoscopic sleeve gastrectomy during closed-loop propofol-remifentanil anaesthesia: A randomised double-blind place
Topics: Adult; Anesthesia, General; Anesthetics, Intravenous; Dexamethasone; Double-Blind Method; Female; Ga | 2016 |
3 other studies available for ondansetron and Obesity
| Article | Year |
|---|---|
Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blood Glucose; Brain; Depression; Depressive Disor | 2014 |
Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission.
Topics: Animals; Anxiety; Behavior, Animal; Body Weight; Brain; Citalopram; Corticosterone; Depression; Diet | 2015 |
Efficacy of single-dose intravenous dolasetron versus ondansetron in the prevention of postoperative nausea and vomiting.
Topics: Adult; Antiemetics; Cholecystectomy, Laparoscopic; Female; Humans; Hysterectomy; Indoles; Injections | 2001 |